Baird raised the firm’s price target on EyePoint to $46 from $33 and keeps an Outperform rating on the shares. The firm said the DAVIO2 topline six-month results exceeded expectations on pretty much every metric which was a near best-case scenario, demonstrating robust efficacy, safety, and durability for EYP-1901 in wet AMD with a dataset that helps de-risk the upcoming Phase 3 studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EYPT:
- EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint management to meet with Cantor Fitzgerald
- EyePoint price target lowered to $25 from $27 at H.C. Wainwright